

PERSONAL INFORMATION

Antonio Giacomo Maria Addis



✉ a.addis@deplazio.it

Sex Male | Date of birth 01/01/1964 | Nationality Italian

POSITION

Researcher at Department of Epidemiology, Regional Health Service, Lazio Region, Rome

WORK EXPERIENCE

-
- 01/01/2018–Present Member of Ethical Committee
Azienda Territoriale Sanitaria Sardegna, Sassari (Italy)
Member of the Committee with pharmacological and regulatory experience for the approval of the studies proposed within Azienda sanitaria territoriale unica in Sardegna
- 16/11/2016–Present Member of Commissione tecnico-scientifica (scientific Committee) assistenza farmaceutica (pharmaceutical assistance)
Regione Sardegna, Cagliari (Italy)
Expert Pharmaceutical Advisor to the Directorate General of Assessorato alla Salute of Sardinia Region
- 01/09/2016–Present Member of Ethical Committee
Ospedale Pediatrico Bambino Gesù, Roma (Vatican city)
- 01/11/2015–Present Member of Commissione Regionale sul Farmaco (Regional Medicine Committee)
Regione Lazio, Roma (Italy)
- 01/12/2012–Present Member of Comitato Tecnico Scientifico (Scientific Committee) of Agenzia Italiana del Farmaco (Italian Medicine Agency)
Agenzia Italiana del Farmaco, Roma (Italy)
- 01/01/2012–31/03/2015 Area Coordinator
Agenzia Sanitaria Sociale Regionale, Regione Emilia Romagna, Bologna (Italy)
■ Lead of the scientific peer review process for the selection of the best proposals within the Programma Ricerca Regione Università (budget 2007-2012 €60 millions).
■ Promotion of the best biomedical and clinical research for Regional Health Service
■ International brokerage for regional clinical and biomedical research and networking at national and international level Monitor of the clinical research done "by and for" the regional health service
- 15/11/2009–31/12/2011 National Expert on secondment
European Medicine Agency
7 Wstferry Circus, London, E14 4HB (United Kingdom)
■ To provide peer reviews of risk management plans for centrally authorised products, particularly on pandemic vaccines and antiviral medicines.

- To conduct signal detection for allocated centrally authorised products and liaise with Rapporteurs for the assessment of the signals.
- Provide expert advice in all areas of pharmacovigilance to support Product Team Leaders, Rapporteurs and scientific committees
- To prepare standard operating procedures and contribute to the preparation of guidelines, position statements, etc..
- Representative in the Pandemic task force, and other expert groups in relation to pharmacovigilance and risk management of pandemic vaccines and antivirals

Business or sector Pharmacovigilance Unit - Risk Management Setion

01/05/2008–01/11/2009

Alternate Member of the Committee for Medicinal Products for Human Use (CHMP)- European Medicine Agency

Agenzia Italiana del Farmaco
via del Tritone 182, 00187 Roma (Italy)

- Rapporteur and assessor for pre-pandemic and pandemic vaccines. • Rapporteur for several centralized medicinal products
- Clinical Assessor for drugs with specific reference to drug use for mother and child health including vaccine.
- Participant to several Scientific committees at national and international level such as the European Task Force for pandemic vaccines or Gruppo di Lavoro sui Vaccini Interministeriale

Business or sector Information, Clinical Trials and Research Department

01/05/2008–01/10/2008

Head of European Drug Assessment Unit (interim)

Agenzia Italiana del Farmaco
via del Tritone 181, 00187 Roma (Italy)

Coordinating the activities for the assessments of drugs authorization (Italy rapporteur) for the Committee for Medicinal Products for Human Use (CHMP)

01/05/2005–14/11/2009

Director of the Drug Information Unit – Information, Clinical Trials and Research Department

Agenzia Italiana del Farmaco
via Sierra Nevada, 00100 Roma (Italy)

- Editor of the National Drug Therapeutic Bulletin
- Coordinator for several educational activities facilitating the transfer of reliable clinical and therapeutic evidence to health operators (e.g., Editor for the Italian edition of the British National Formulary and CLinical Evidence);
- Coordinator for the AIFA continuous medical education programme based on Clinical Evidence and other sources Evidence Based
- Representing the National Medicine Agency (AIFA) in the National System of Guidelines
- Health Technology assessment projects

Business or sector Information, Clinical Trials and Research Department

01/07/2002–31/05/2005

Head of Drug Information Unit

Ministry of Health
via della Civiltà Romana, 00100 Roma (Italy)

- Responsible for the editorial activities of the Directorate General of Medicines and Medical Devices (Ministry of Health)
- Coordination of several drug utilization studies with the aims to collect pharmacoepidemiological data useful for regulatory decisions.
- National regulatory activities concerning risk communication and pharmacovigilance including

vaccines.

■ Health Technology assessment projects

I have been coordinator for the publication of the National Pharmaceutical Formulary
Business or sector Ministry of Health – Directorate General of Medicines and Medical Devices, Roma,
Italy

- 01/07/2000–30/06/2002 Full time Resercher
Center for the evaluation of effectiveness of health care (CeVEAS) Centro per la
Valutazione dell'Efficacia e dell'Assistenza Sanitaria, Modena, Italy
viale Muratori 201, Modena (Italy)
Health Technology Assessment programme regarding drug therapies
Clinical assessor in the Panel of National Guideline System (SNLG) Italian evidence-based guidelines
for the management of influenza-like syndrome in adults and children
Responsible and principal investigator for Drug utilization studies and Pharmacoepidemiology
Business or sector Health Techology Assessment
- 02/09/1997–30/06/2002 Full time Researcher
"Mario Negri" Institute for Pharmacological Research, Milano, Italy
Via Eritrea 62, Milano (Italy)
Principal investigator for studies regarding the definition of safety of drugs use in pregnancy and
during the first years of life.
Design and coordination for several pharmacoepidemiological studies on drug use in pregnancy and in
children including vaccines.
Principal investigator for meta-analysis of drug safety data with observational studies.
Responsible for the Drug Information Center of the Istituto di Ricerche Farmacologiche "Mario Negri"
Collaboration with several Drug Therapeutic Bulletin (ISDB) with special focus on the drug safety on
children and during pregnancy.
Business or sector Laboratory for Mother and Child Health
- 01/02/1995–01/09/1997 Visiting Scientist
University of Toronto, Faculty of Pharmacy, Toronto, Canada
144 College Street, M5S 3M2 Toronto (Canada)
Assistant professor in the sector of Pharmacoepidemiology.
Principal investigator for meta-analysis of drug safety data with observational studies
Principal investigator of pharmacoepidemiological and pharmacoconomics studies.
Pharmacovigilance studies regarding the benefit risk profile of drug use for mother and child health.
Business or sector Pharmacoepidemiology
- 02/02/1995–01/09/1997 Post-doctoral Fellow
The Hospital for Sick Children, Toronto, Canada
555 UNIVERSITY AVE, M5G 1X8 Toronto (Canada)
Studies regarding the definition of safety of drugs use in pregnancy and during the first years of life.
Design and coordination of pharmacoepidemiological studies on drug use in pregnancy and in children.
Researcher for the Motherisk programme performing pharmacoepidemiology studies (cohort, case
control, meta-analysis studies) on drug use in pregnancy and children.
Business or sector Division of CLinical Pharmacology
- 01/01/1994–02/02/1995 Post doctoral Fellow
"Mario Negri" Institute for Pharmacological Research, Milano, Italy

via Eritrea 62, Milano (Italy)

Studies regarding the definition of safety of drugs use in pregnancy and during the first years of life.

Designed and coordination as principal investigator of pharmacoepidemiological studies (prospective and retrospective cohort studies) on drug use in pregnancy and in children including vaccines

Business or sector Laboratory for Mother and Child Health

EDUCATION AND TRAINING

- 01/08/1991–24/06/1993 **PhD Fellow on Pharmacological Research** Post Graduate - Specialization in Pharmacological Research Ph D Equivalent
- School of Region Lombardia, "Mario Negri" Institute for Pharmacological Research, Milano, Italy
via Eritrea 62, Milano (Italy)
- PhD Fellow at the Regional School for Pharmacological research.
Studies on drug safety in pregnancy and in children.
Drug Utilization in pregnancy and analysis of safety of new vaccines such as MMR and Pertussis in children.
Researcher on pharmacoepidemiological studies on use of drug in children and in pregnant women
- 01/09/1988–31/07/1991 **Fellow as civil servant** Trainee
- "Mario Negri" Institute for Pharmacological Research, Milano, Italy
via Eritrea 62, Milano (Italy)
- Trainee in the the Laboratory of cholinergic system doing basic non clinical research on animal model for CNS Drugs
- 01/09/1983–01/07/1991 **Graduation on Chemical Pharmacy** Dottore in Chimica e Tecnologia Farmaceutica
- Faculty of Chemical Pharmacy - Universita' Statale di Milano, Milan, Italy
via Bartolini, Milano (Italy)
- Chemical and Technological Pharmacy Milano, Italy
- The course of Chemical Pharmacy in Italy is of 5 years with compulsory discussion of experimental thesis before the final graduations.
- I spent the last two years of my university course working in the Laboratory of cholinergic system of the Mario Negri Insitute studying on animal models the activity of several CNS drugs
- 01/09/1978–30/06/1983 **High level school degree** Diploma di Maturita' Classica
- Liceo Classico Bernardo Demuro
00729 Tempio Pausania, Sassari (Italy)

PERSONAL SKILLS

Mother tongue(s) Italian

Foreign language(s)	UNDERSTANDING		SPEAKING		WRITING
	Listening	Reading	Spoken interaction	Spoken production	
English	C2	C2	C2	C2	C2
Spanish	A2	A2	A2	A2	A2

French

A2

A1

A2

A2

A1

Levels: A1 and A2: Basic user - B1 and B2: Independent user - C1 and C2: Proficient user
Common European Framework of Reference for Languages

Communication skills I dedicate most of my time extra work to follow my two children enjoying the family duties.

Organisational / managerial skills I had several appointments at international level, mostly representing the Italian Medicine Agency and/or the Ministry of Health (e.g., Pharmaceutical Forum – Working Group on Relative Effectiveness 2007-2008; Pharmaceutical Forum – Public Private Partnership on Information to Patients; HMA WGCP HMA WG Communication Professionals- EMEA 2007-2008

Job-related skills Thorough knowledge and experience of European Pharmaceutical Legislation and Industry gained in one EU country and at EMEA level.
 Expertise in European/International Regulatory Affairs and Prescribing Information issues in particular.
 Experienced on Pharmacoepidemiology and Drug Information research in term of design, conduct and assess ad hoc studies
 Experienced on Drug use in mother and child health including vaccine
 Experience on Drug Information techniques, medical writing and editorial activities
 Rapporteur and assessor for pre-pandemic and pandemic vaccines
 Clinical Assessor for drugs with specific reference to drug use for mother and child health including vaccine.
 Experienced in Drug Utilization and Pharmaco-economical analysis.
 Experience on bibliographic search and on scientific literature databases

Digital skills

SELF-ASSESSMENT

Information processing	Communication	Content creation	Safety	Problem-solving
Proficient user	Proficient user	Proficient user	Independent user	Independent user

Digital skills - Self-assessment grid

Eudravigilance certificated user.

Experience on data analysis and special expertise with programme to retrieve from bibliographic databases with the aim to perform meta-analysis.

I am user friendly of MS Word for Windows (Advanced), MS Outlook, MS Excel, MS PowerPoint, Reference manager and EPI INFO.

Experience on data retrieval from literature databases

Other skills I am an avid reader.

I regularly swim and I loved sailing. I also play chess. Cinema has always been my passion. I enjoyed writing for some web base magazines commentaries on new movies releases.

ADDITIONAL INFORMATION

Author of 145 publications (https://www.researchgate.net/profile/Antonio_Addis)

Selection of Publications in peer reviewed journals and Scientific Books

H INDEX (web of science) = 25

■ Belleudi V, Trotta F, Pinnarelli L, Davoli M, Addis A. Neonatal outcomes following new

- reimbursement limitations on palivizumab in Italy. *Arch Dis Child*. 2018 Dec;103(12):1163-1167.
- Belleudi V, Trotta F, Vecchi S, Amato L, Addis A, Davoli M. Studies on drug switchability showed heterogeneity in methodological approaches: a scoping review. *J Clin Epidemiol*. 2018;101:5-16.
 - Addis A. Biosimilars: Italian Medicines Agency takes position. *Recenti Prog Med*. 2018;109:214-215.
 - Marcianò I, Ingrassiotta Y, Giorgianni F, Ientile V, Chinellato A, Tari DU, Gini R, Cannavò S, Pastorello M, Scondotto S, Cananzi P, Traversa G, Trotta F, Belleudi V, Addis A, Trifirò G. (2018) Pattern of Use of Biosimilar and Originator Somatropin in Italy: A Population-Based Multiple Databases Study During the Years 2009–2014. *Front. Endocrinol*. 9:95.
 - Di Domenicantonio R, Trotta F, Cascini S, Agabiti N, Kohn A, Gasbarrini A, Davoli M, Addis A. Population-based cohort study on comparative effectiveness and safety of biologics in inflammatory bowel disease. *Clin Epidemiol*. 2018;10:203-213.
 - Addis A, Davoli M. Fare epidemiologia della ricerca per non disperdere le risorse del servizio sanitario nazionale. *Epidemiol Prev* 2018; 42: 96-97.
 - Belleudi V, Addis A. Switch: come passare indenni da un farmaco all'altro *Recenti Prog Med*. 2017;108:451-453.
 - Addis A. Big data contro studi clinici randomizzati? La contrapposizione non giova a nessuno. *Epidemiol Prev*. 2017;41:304-305.
 - Busard CI, Cohen AD, Wolf P, Gkalkakiotis S, Cazzaniga S, Stern RS, Hutten BA, Feldhamer I, Quehenberger F, Lichem R, Kojanova M, Adenubiova E, Addis A, Naldi L, Spuls PI. Biologics combined with conventional systemic agents or phototherapy for the treatment of psoriasis: real-life data from PSONET registries. *J Eur Acad Dermatol Venereol*. 2018;32:245-253.
 - Addis A, Trotta F, Tafuri G, De Fiore L. Information needs on precision medicine: a survey of Italian health care professionals. *Ann Ist Super Sanita*. 2018;54:316-323
 - Amato L, Addis A, Saule R, Trotta F, Mitrova Z, Davoli M. Comparative efficacy and safety in ESA biosimilars vs. originators in adults with chronic kidney disease: a systematic review and metaanalysis. *J Nephrol* 2017. DOI: 10.1007/s40620-017-0419-5 [Epub ahead of print]
 - Addis A, Trotta F. Qual è il giusto place in therapy dell'olmesartan? *Glob Reg Health Technol Assess* 2017; e141-e144.
 - Trotta F, Mayer F, Mecozzi A, Amato L, Addis A. Impact of Guidance on the Prescription Patterns of GCSFs for the Prevention of Febrile Neutropenia Following Anticancer Chemotherapy: A Population- Based Utilization Study in the Lazio Region. *BioDrugs* 2017; 31:117-124.
 - Trotta F, Belleudi V, Fusco D, Amato L, Mecozzi A, Mayer F, Sansone M, Davoli M, Addis A. Comparative effectiveness and safety of erythropoiesis-stimulating agents (biosimilars vs originators) in clinical practice: a population-based cohort study in Italy. *BMJ Open* 2017; 7:e011637. doi:10.1136/bmjopen-2016-011637.
 - Barbui C, Addis A, Amato L, Traversa G, Garattini S. Can systematic reviews contribute to regulatory decisions? *Eur J Clin Pharmacol*. 2017;73:507-509.
 - Addis A, Rosa A. Luci e ombre dei big data. *Quaderni ACP* 2017;243(3):97.
 - Bortolus R, Parazzini F, Addis A. Folic Acid for the Prevention of Neural Tube Defects. *JAMA Pediatr*. 2017;171:709-710.
 - Perrone F, Addis A, Sinagra G, Bruzzi P. Ricerca clinica, tra presunti sprechi e governance dell'innovazione. *Recenti Prog Med*. 2017;108:207-210.
 - Illario M, De Luca V, Tramontano G, Menditto E, Iaccarino G, Bertorello L, Palummeri E, Romano V, Moda G, Maggio M, Barbolini M, Leonardini L, Addis A; Italian EIP-AHA Working Group. The Italian reference sites of the European innovation partnership on active and healthy ageing: Progetto Mattone Internazionale as an enabling factor. *Ann Ist Super Sanita*. 2017;53:60-69.
 - Trotta F, Addis A. Equivalenza, equità di accesso e prove di efficacia per l'uso dei biosimilari. *Recenti Prog Med*. 2017;108:11-13.
 - Addis A, Traversa G. Trattamento del vomito da gastroenterite: quando il bisogno clinico chiama e la ricerca risponde. *Medico e Bambino* 2017;36(1):7-8.
 - Garcia-Doval I, Cohen AD, Cazzaniga S, Feldhamer I, Addis A, Carretero G, Ferrándiz C, Stern RS, Naldi L; Psonet Network. Risk of serious infections, cutaneous bacterial infections, and granulomatous infections in patients with psoriasis treated with anti-tumor necrosis factor agents versus classic therapies: Prospective meta-analysis of Psonet registries. *J Am Acad Dermatol*. 2017;76:299-308.e16.

- Naldi L, Cazzaniga S, di Mercurio M, Grossi E, Addis A. PSOCARE study. Inequalities in access to biological treatments for psoriasis: results from the Italian Psocare registry. *Br J Dermatol*. 2017;176:1331-1338.
- Addis A, De Fiore L, Traversa G. Ricerca scientifica tra filantropia e scarcity. *Recenti Prog Med* 2016;107:507-509.
- Addis A, Davoli M. Governance dell'innovazione per dispositivi medici cardiovascolari: se le evidenze non bastano. *Recenti Prog Med* 2016; 107(1): 7-9.
- Di Furia L, Rusciano MR, Leonardini L, Rossi P, Giammarchi C, Vittori E, Tibocca S, Russo FL, Montuori P, Triassi M, Nardone A, Giaimo MD, Migazzi M, Piffer S, Iaria A, Trapasso A, Firenze A, Cristaudo R, Revello M, Castiglioni A, Zagonel V, Iaccarino G, Addis A, Natale L, Di Somma C, Colao A, Perra A, Giova K, Montuori N, Ilario M. A Nutritional Approach to the Prevention of Cancer: from Assessment to Personalized Intervention. *Transl Med UniSa* 2016;13:33-41.
- Addis A, Papini D, Bassi MC, Grilli R. PRIER II. The Emilia-Romagna Research and Innovation Programme *Recenti progressi in medicina* 2015;106:409-415
- Addis A, Costa E, De Palma R, Magrini N, Marata AM, Martelli L, Papini D Considerations on limits and profits of registries *Recenti progressi in medicina* 2015; 106:425-435.
- Addis A, Berti E, De Palma R, Fiori G, Papini D, Traversa G Considerations on what we can (and what we should not) ask to registries *Recenti progressi in medicina* 2015;106:444-454.
- Bousquet J, Addis A, Adcock I, Agache I, Agustí A, Alonso A, et. al. Integrated care pathways for airway diseases (AIRWAYS-ICPs). *European respiratory journal* 2014;44:304-323.
- Mazzocchetti A, Caranci N, Addis A. Invecchiamento della popolazione e implicazioni sulla salute. Riflessioni sull'andamento nel tempo in Emilia-Romagna. *Recenti Progressi in Medicina* 2014;105:191-197.
- Addis A, Martini N. Dalle note limitative ai registri AIFA. *Recenti Progressi in Medicina* 2013;104:229-235.
- Poole D, Rossi C, Addis A, Livigni S, Bertolini G. Drotrecogin alfa (activated) in severe sepsis. *Lancet Infect Dis*. 2013;13:107-8.
- Dodd CN, and Global H1N1 GBS Consortium (Addis A.). International collaboration to assess the risk of Guillain Barré Syndrome following Influenza A (H1N1) 2009 monovalent vaccines. *Vaccine* 2013;31: 4448-58.
- Palmieri L, Rielli R, Demattè L, Donfrancesco C, La Terza G, De Sanctis Caiola P, Dima F, Lo Noce C, Giannelli AM, Brignoli O, Cuffari A, De Rosa M, Addis A, Laurendi G, Giampaoli S. Cardiovascular Risk Observatory: preliminary results *G Ital Cardiol*. 2010;11:154-61.
- Tedeschi G, Amato MP, D'Alessandro R, Drago F, Milanese C, Popoli P, Rossi P, Savettieri G, Tola MR, Vanacore N, Covezzoli A, De Rosa M, Comi G, Pozzilli C, Bertolotto A, Marosu MG, Grimaldi LM, Piccinni C, Montanaro N, Periotto L, Iommelli R, Addis A, Martini N, Provinciali L, Mancardi GL. The pharmacovigilance program on natalizumab in Italy: 2 years of experience. *Neurol Sci*. 2009 Suppl 2:S163-5.
- Joppi R, Demattè L, Menti AM, Pase D, Poggiani C, Mezzalana L; Italian Horizon Scanning Project Group. The Italian Horizon Scanning Project. *Eur J Clin Pharmacol*. 2009;65:775-81.
- Naldi L, Addis A, Chimenti S, Giannetti A, Picardo M, Tomino C, Maccarone M, Chatenoud L, Bertuccio P, Caggese E, Cuscito R. Impact of body mass index and obesity on clinical response to systemic treatment for psoriasis. Evidence from the psocare project. *Dermatology*. 2008;217:365-373.
- Mancardi GL, Amato MP, D'Alessandro R, Drago F, Milanese C, Popoli P, Provinciali L, Rossi P, Savettieri G, Tedeschi G, Tola MR, Vanacore N, Covezzoli A, De Rosa M, Piccinni C, Montanaro N, Periotto L, Addis A, Martini N. Natalizumab: a country-based surveillance program. *Neurol Sci*. 2008 Sep;29 Suppl 2:S235-7.
- Addis A, Deambrosis P, Martini N The Italian criteria for the reimbursement of innovative advanced therapies. *Challenges in New Advanced Therapies*, Eds. G. Nisticò, M. Papaluca Amati & D. Brasseur.(EXORMA) 2008;105-114.
- Moja L, Moschetti I, Cinquini M, Sala V, Compagnoni A, Duca P, Deligant C, Manfrini R, Clivio L, Satolli R, Addis A, Grimshaw JM, Dri P, Liberati A. Clinical Evidence Continuous Medical Education: a randomised educational trial of an open access e-learning program for transferring evidence-based information - ICEKUBE (Italian Clinical Evidence Knowledge Utilization Behaviour Evaluation) - Study protocol Implementation. *Science Biome Central* 2008;3:37.
- Bertolini G, Rossi C, Anghileri A, Livigni S, Addis A, Poole D. Response to the letter by Williams et

- al. *Intensive Care Med.* 2007;33:1490-1.
- Moja L, Moschetti I, Liberati A, Manfrini R, Deligant C, Satolli R, **Addis A**, Martini N, Dri P. Using Clinical Evidence in a national continuing medical education program in Italy. *PLoS Med.* 2007;4:113.
 - Bertolini G, Rossi C, Anghileri A, Livigni S, **Addis A**, Poole D. Use of Drotrecogin alfa (activated) in Italian intensive care units: the results of a nationwide survey. *Intensive Care Med.* 2007;33:426-34.
 - Mastroiacovo P, Addis A Folic acid: a public-health challenge. *Lancet* 2006;367:2057.
 - Giampaoli S, Palmieri L, Donfrancesco C, Panico S, Pilotto L, **Addis A**, Boccanelli A, Di Pasquale G, Brignoli O, Filippi A, Vanuzzo D. Assessment of the absolute global cardiovascular risk: comparison between the risk chart and the individual score of the CUORE Project. *Giornale italiano di cardiologia.* 2006;7:359-64.
 - **Addis A**, Martini N. EBM e politica del farmaco. In: Liberati A, ed. *Etica, conoscenza e sanità.* Il Pensiero Scientifico Editore 2005;337-351.
 - **Addis A**, co-author. *Usa e applicazione della carta del rischio cardiovascolare.* Il Pensiero Scientifico Editore 2005.
 - Giampaoli S, Vanuzzo D, Palmieri L, Panico S, Lo Noce C, Dima F, Donfrancesco C, Troiani M, Greco D, D'Argenio P, Laurendi G, **Addis A**. *Prevenzione, fattori di rischio e stili di vita. Rischio cardiovascolare globale assoluto. Rapporto Osservasalute 2005. Stato di salute e qualità dell'assistenza nelle regioni italiane.* Prex S.p.a. Editore: 271-272.
 - Giampaoli S, Palmieri L, Donfrancesco C, Panico S, Pilotto L, **Addis A**, Boccanelli A, Di Pasquale G, Brignoli O, Filippi A, Ventriglia G, Vanuzzo D a nome del Gruppo di ricerca dell'Osservatorio Epidemiologico cardiovascolare. Progetto Cuore I.S.S.: carta e punteggio. *Società Italiana di Medicina Generale* 2005;5/6:17-22.
 - **Addis A.** (co-ed) *The motherisk Guide to Cancer in Pregnancy and Lactation.* Koren G, Lishner M, Santiago S eds. The Hospital for Sick Children. 2005.
 - **Addis A.** *Prevenzione delle malattie cardiovascolari: il ruolo dell'organo regolatore.* *Ital Heart J.* 2004;5 Suppl 8:73S-77S; discussion 84S-85S, 116S-121S.
 - Filibeck U, **Addis A**, Tomino C, Martini N. European Clinical Trials Directive: the Italian position. *Lancet.* 2004;363:1651-2.
 - Rocchi F, **Addis A**, Martini N. Current national initiatives about drug policies and cost control in Europe: the Italy example. *Journal of Ambulatory Care Management.* 2004;27:127-31.
 - Folino-Gallo P, **Addis A**, Bruzzone M, Conforti A, Moretti U, Leone R, Tosolini F, Velo G. *L'assistenza farmaceutica territoriale. Rapporto Osservasalute 2003. Stato di salute e qualità dell'assistenza nelle regioni italiane.* Vita e pensiero Editore: 275-89.
 - Formoso G, Moja L, Nonino F, Dri P, **Addis A**, Martini N, Liberati A. Clinical Evidence: a useful tool for promoting evidence-based practice? *BMC Health Serv Res.* 2003 Dec 23;3:24.
 - Traversa G, Magrini N, **Addis A.** e Gruppo di lavoro OsMed. *Il consumo e la spesa farmaceutica: una valutazione comparata tra regioni. I servizi sanitari in Italia.* Il Mulino. 2003.
 - EURO-MED-STAT Group. Monitoring expenditure and utilization of medicinal products in the European Union countries: a public health approach. *Eur J Public Health.* 2003;13:95-100.
 - Einarson A, Bonari L, Voyer-Lavigne S, **Addis A**, Matsui D, Johnson Y, Koren G. A multicentre prospective controlled study to determine the safety of trazodone and nefazodone use during pregnancy. *Can J Psychiatry.* 2003;48:106-10.
 - Moretti ME, Caprara D, Coutinho CJ, Bar-Oz B, Berkovitch M, **Addis A**, Jovanovski E, Schuler-Faccini L, Koren G. Fetal safety of loratadine use in the first trimester of pregnancy: a multicenter study. *J Allergy Clin Immunol.* 2003;111:479-83.
 - **Addis A**, Magrini N. New approaches to analysing prescription data and to transfer pharmacoepidemiological and evidence-based reports to prescribers. *Pharmacoepidemiol Drug Saf.* 2002;11:721-6.
 - Berkovitch M, Mazzota P, Greenberg R, Elbirt D, **Addis A**, Schuler-Faccini L, Merlob P, Arnon J, Stahl B, Magee L, Moretti M, Ornoy A. Metoclopramide for nausea and vomiting of pregnancy: a prospective multicenter international study. *Am J Perinatology* 2002;19:311-6.
 - Buzzetti R, D'Amico R, **Addis A.** New drug treatment for asthma: clinical versus statistical significance. *Journal of Pediatrics* 2002; 140:484.
 - Iskedjian M, Einarson TR, MacKeigan LD, Shear N, **Addis A**, Mittmann N, Ilersich AL. Relationship between daily dose frequency and adherence to antihypertensive pharmacotherapy:

- evidence from a meta-analysis. *Clinical Therapeutics*. 2002;24:302-16.
- Di Gianantonio E, Schaefer C, Mastroiacovo P, Cournot MP, Benedicenti F, Reuvers V, Occupati B, Robert E, Bellemín B, Addis A, Aron J, Clementi M. Adverse effects of prenatal methimazole exposure. *Teratology* 2001;64:262-66.
 - Oh PI, Iskedjian M, Addis A, Lanctot K, Einarson TR. Pharmacoeconomic evaluation of clozapine in treatment-resistant schizophrenia: a cost-utility analysis. *Can J Clinical Pharmacology* 2001;18:199-206.
 - Einarson A, Fatoye B, Sarkar M, Lavigne S, Brochu J, Chambers C, Mastroiacovo P, Addis A, Matsui D, Schuler L, Einarson TR, Koren G. Pregnancy Outcome Following Gestational Exposure to Venlafaxine: A Multicenter Prospective Controlled Study. *Am J Psychiatry* 2001;158: 1728-1730.
 - Addis A, Assael Barouk M, Raimo F I farmaci essenziali in pediatria di famiglia Utet Div. Scienze Mediche, Milano, 2001
 - Addis A, Moretti ME, Fayyazuddin AS, Einarson TR Fetal effects of cocaine: an updated meta-analysis. *Reproductive Toxicology* 2001;15: 341-69.
 - Addis A, Magrini N, Mastroiacovo P. Drug use in pregnancy. *Lancet* 2001;357:800.
 - Addis A, Schuler L, Moretti ME, Bonati M, Koren G. Teratogen information services around the world. In: *Maternal-Fetal Toxicology*, 3rd Edition, Koren G.(ed), Dekker, New York 2001.
 - Addis A, Moretti ME, Syed FA, Einarson TR, Koren G.: Cocaine exposure during pregnancy: A new meta-analysis. In: *Maternal-Fetal Toxicology*, 3rd Edition, Koren G.(ed), Dekker, New York 2001.
 - Dolovich LR, Addis A, Régis Vaillancourt JM, Barry Power JD, Koren G, and Einarson TR Benzodiazepine use in pregnancy and major malformations or oral cleft: meta-analysis of cohort and case-control studies In: *Maternal-Fetal Toxicology*, 3rd Edition, Koren G.(ed), Dekker, New York 2001.
 - Bonati M, Addis A.: Pregnancy. In: *Clinical Pharmacology*, Sirtori C, Reidenberg M, Kuhlman, J (eds.) McGraw-Hills International 2000.
 - Vargas FR, Schuler-Faccini L, Brunoni D, Kim C, Meloni VFA, Sugayama SMM, Albano L, Llerena JC, Almeida JCC, Duarte A, Cavalcanti DP, Goloni-Bertollo E, Conte A, Koren G and Addis A. Prenatal exposure to misoprostol and vascular disruption defects: a case control study. *Am J Med Genet* 2000;95:302-06.
 - Opasich C, Russo A, Colombo E, Aldrovandi M, Addis A, Tavazzi L Your cardiac patient wants to become a mother. Risk considerations and advice Part II Your cardiac patient is pregnant. *Ital Heart J* 2000;1: 667-73.
 - Opasich C, Russo A, Catalano O, Criffo A, De Feo S, Addis A, Tavazzi L Your cardiac patient wants to become a mother. Risk considerations and advice Part I Your cardiac patient ask advice on a possible pregnancy. *Ital Heart J* 2000;1:605-12.
 - Addis A, Sharabi S, Bonati M. Risk classification system for drug use during pregnancy. Are they a reliable source of information? *Drug Safety* 2000;23:245-53.
 - Berkovitch M, Elbirt D, Addis A, Schuler-Faccini L, Ornoy A. Fetal effects of metoclopramide therapy for nausea and vomiting of pregnancy. *New England Journal of Medicine* 2000;343:445-6.
 - Einarson A, Mastroiacovo P, Aron J, Ornoy A, Addis A, Malm H, Koren G. A prospective controlled multicentre study of loperamide in pregnancy. *Canadian Journal of Gastroenterology* 2000;14:185-87.
 - Addis A, Dolovich LR, Einarson TR, Koren G. Can one use anxiolytics during pregnancy without anxiety? *Canadian Family Physician Journal* 2000;46:549-51.
 - Addis A, Koren G. Safety of fluoxetine during the first trimester of pregnancy: meta-analytical review of epidemiological studies. *Psychological Medicine* 2000;30:89-94.
 - Addis A, Bonati M. Use of nimesulide in children. *Lancet* 1999;354:1034.
 - Addis A, Loebstein R, Koren G, Einarson TR. Meta-analytic review of clinical effectiveness of oral deferiprone (L1). *European Journal of Clinical Pharmacology* 1999;55:1-6.
 - Mastroiacovo P, Mazzone T, Addis A, Elephant E, Carter P, Garbis H, Robert E, Bonati M, Ornoy A, Finardi A, Schaffer C, Caramelli L, Rodriguez-Pinilla E, Clementi M. High Vitamin A intake in early pregnancy and congenital malformations: a multicentre prospective controlled study. *Teratology* 1999;59:7-11.
 - Loebstein R, Lalkin A, Addis A, Costa A, Lalkin I, Bonati M, Koren G. Pregnancy outcome following gestational exposure to terfenadine: a multicenter prospective controlled study. *Journal of*

Allergy and Clinical Immunology 1999;104:953-6.

- Bonati M, **Addis A**. Informing women about drugs they take during pregnancy: promoting consumers' drug information as integral part of care. *Pharmacy world & Science* 1998;20:236-7.
- Einarson A, Phillips E, Mawji F, D'Alimonte D, Schick B, **Addis A**, Mastroiacovo P, Mazzone T, Matsui D, Koren G. A prospective controlled multicentre study of clarithromycin in pregnancy. *American Journal of Perinatology* 1998;15:523-5.
- Koren G, Nulman I, **Addis A**. Outcome of children exposed in utero to fluoxetine: a critical review. *Depression Anxiety* 1998;8:27-31.
- Lalkin A, Loebstein R, **Addis A**, Ramezani-Namin F, Mastroiacovo P, Mazzone T, Vial T, Bonati M, Koren G. The safety of omeprazole during pregnancy: a multicenter prospective controlled study. *American Journal Obstetric Gynecology* 1998;179:727-30.
- Dolovich LR, **Addis A**, Vaillancourt JM, Power JD, Koren G, Einarson TR. Benzodiazepine in pregnancy and major malformations or oral cleft: meta-analysis of cohort and case-control studies. *British Medical Journal* 1998;317:839-43.
- Lalkin A, Loebstein R, **Addis A**, Koren G. Therapeutic approach to hypertension during pregnancy. *Canadian Family Physician Journal* 1998;44:1245-7.
- Loebstein R, **Addis A**, Ho E, Andreou R, Sage S, Donnenfeld AE, Schick B, Bonati M, Moretti M, Lalkin A, Pastuszak A, Koren G. Pregnancy outcome following gestational exposure to fluoroquinolones: a multicenter prospective controlled study. *Antimicrobial Agents and Chemotherapy* 1998;42:1336-9.
- Gruppo collaborativo SPT. Uso di psicofarmaci nelle donne in età fertile che accedono ai servizi psichiatrici territoriali. *Rivista Sperimentale di Freniatria* 1998;4:252-60.
- Einarson TR, **Addis A**, Mittmann N, Iskedjian M. Meta-analysis of venlafaxine, SSRIs and TCAs in the treatment of major depressive disorder. *Canadian Journal of Clinical Pharmacology* 1998;5:205-16.
- Iskedjian M, Trakas K, Bradley CA, **Addis A**, Lactot K, Kruk D, Ilersich AL, Einarson TR. Quality assesment of economic evaluations published in *Pharmacoeconomics*. The first four years (1992-1995). *Pharmacoeconomics* 1997;12:685-94.
- Lalkin A, Magee L, **Addis A**, Loebstein R., Koren G.: Acid-suppressing drugs during pregnancy. *Canadian Family Physician Journal* 1997;43: 1923-4, 1926.
- Bailey B, **Addis A**. Asthma during pregnancy. *Canadian Family Physician Journal* 1997; 43: 1717-8.
- Bailey B, **Addis A**, Lee A, Sanghvi K, Mastroiacovo P, Mazzone T, Bonati M, Paolini C, Garbis H, Val T, De Souza CF, Matsui D, Schechtman AS, Conover B, Lau M, Koren G. Cisapride use during human pregnancy: a prospective, controlled multicenter study. *Digestive Diseases and Sciences* 1997; 42: 1848-52.
- Einarson TR, **Addis A**, Iskedjian M. Pharmacoeconomic analysis of venlafaxine in the treatment of major depressive disorder. *Pharmacoeconomics* 1997; 12: 286-96.
- Trakas K, **Addis A**, Kruk D, Buczek Y, Iskedjian M, Einarson TR. Quality assessment of pharmacoeconomic abstracts of original research articles in selected journals. *Annals of Pharmacotherapy* 1997;31:423-8.
- **Addis A**, Blowey D, Koren G. Tuberculosis during pregnancy. *Canadian Family Physician Journal* 1996; 42:1461-2.
- Oh PI, Einarson TR, Iskedjian M, **Addis A**, Lanctôt K. Pharmacoeconomic evaluation of risperidone and clozapine in chronic and treatment-resistant schizophrenia. Ottawa Canadian Coordinating Office for Health Technology Assessment (CCOHTA) 1996.
- **Addis A**, Impicciatore P, Miglio D, Colombo F, Bonati M, Da Silva CD. Drug use in pregnancy and lactation: the work of a regional drug information centre. *Annals of Pharmacotherapy* 1995; 29:632-3.
- Bonati M, Nannini S, **Addis A**. Vitamin A supplementation during pregnancy in developed countries. *Lancet* 1995; 345:736-7.
- **Addis A**, Miglio D., Da Silva C.D.C., Colombo Fabio, Bonati M.: Drug use in pregnancy from the viewpoint of a regional drug information centre. In: *Health information centres in Europe. What is their status? How should they develop?* Bonati M., Tognoni G. (eds); IRFMN, Milano 1995; 23-26
- Forloni G, Angeretti N, Amoroso D, **Addis A**, Consolo S. Decrease in [³H] hemicholinium binding to high-affinity choline uptake sites in deafferented striatum: restoration by oxiracetam. *Brain*

Research 1990; 530:156-60.

Autorizzo il trattamento dei dati personali contenuti nel mio curriculum vitae in base al Regolamento europeo UE 2016/679

Rome, 15-04-2019

